MESO vs. SWTX, APGE, IOVA, ACLX, DNLI, TWST, VCEL, IMCR, ADMA, and CGON
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), Immunocore (IMCR), ADMA Biologics (ADMA), and CG Oncology (CGON). These companies are all part of the "biological products, except diagnostic" industry.
SpringWorks Therapeutics (NASDAQ:SWTX) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, SpringWorks Therapeutics and SpringWorks Therapeutics both had 6 articles in the media. SpringWorks Therapeutics' average media sentiment score of 0.87 beat Mesoblast's score of 0.75 indicating that Mesoblast is being referred to more favorably in the news media.
SpringWorks Therapeutics' return on equity of 0.00% beat Mesoblast's return on equity.
Mesoblast has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics presently has a consensus target price of $68.83, suggesting a potential upside of 68.46%. Mesoblast has a consensus target price of $13.67, suggesting a potential upside of 70.41%. Given SpringWorks Therapeutics' higher possible upside, analysts plainly believe Mesoblast is more favorable than SpringWorks Therapeutics.
SpringWorks Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500.
1.4% of Mesoblast shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mesoblast received 313 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 70.45% of users gave Mesoblast an outperform vote while only 68.18% of users gave SpringWorks Therapeutics an outperform vote.
Summary
Mesoblast beats SpringWorks Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesoblast Competitors List
Related Companies and Tools
